2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Material Contracts
Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Announces Reverse Stock Split
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Material disclosure
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload